Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

Short summary

Dupilumab treatment (200 mg weekly) for 16 weeks progressively normalized lesional skin gene expression in moderate-to-severe atopic dermatitis (AD) patients, shifting it toward a nonlesional phenotype by 110.8% vs. placebo (-10.5%).

AI-generated from the title and abstract; the full text is not read.